Standout Papers

Recommendations for Human Epidermal Growth Factor Receptor ... 2005 2026 2012 2019 3.0k
  1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update (2013)
    Antonio C. Wolff, M. Elizabeth Hammond et al. Journal of Clinical Oncology
  2. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer (2007)
    Kathy D. Miller, Molin Wang et al. New England Journal of Medicine
  3. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update (2013)
    Antonio C. Wolff, M. Elizabeth Hammond et al. Archives of Pathology & Laboratory Medicine
  4. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 (2014)
    Sylvia Adams, Robert J. Gray et al. Journal of Clinical Oncology
  5. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 (2005)
    Paul E. Goss, James N. Ingle et al. JNCI Journal of the National Cancer Institute
  6. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer (2011)
    Nicholas J. Robert, Véronique Dièras et al. Journal of Clinical Oncology
  7. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer (2008)
    Joseph A. Sparano, Molin Wang et al. New England Journal of Medicine
  8. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 (2014)
    Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology
  9. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes (2005)
    Matthew P. Goetz, James M. Rae et al. Journal of Clinical Oncology
  10. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer (2006)
    Donald A. Berry, Constance Cirrincione et al. JAMA
  11. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines (1999)
    Richard J. Gralla, David Osoba et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 4 from Science/Nature 142 standout
Sub-graph 1 of 14

Citing Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
1 intermediate paper

Works of Edith A. Perez being referenced

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
2011 Standout
HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
2006

Author Peers

Author Last Decade Papers Cites
Edith A. Perez 20395 10865 5671 6462 395 29.5k
W. Eiermann 16006 9766 4460 4818 223 23.2k
Clifford A. Hudis 23054 13808 6733 8120 509 38.8k
Jonas Bergh 15296 11360 4816 10934 510 28.3k
Kathleen I. Pritchard 15195 9674 5236 5962 368 24.8k
Antonio C. Wolff 15460 10354 4737 5361 352 24.0k
Karen A. Gelmon 15458 6840 6371 5516 389 23.1k
Vicente Valero 16929 12970 4789 5329 495 27.2k
George W. Sledge 14481 9362 6145 7375 435 24.8k
Aron Goldhirsch 20081 16911 5970 5590 488 32.8k
James N. Ingle 13634 9237 3939 5508 360 23.1k

All Works

Loading papers...

Rankless by CCL
2026